Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
34.42
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-4.64 Insider Own22.67% Shs Outstand34.21M Perf Week-4.07%
Market Cap1.29B Forward P/E- EPS next Y-1.76 Insider Trans-1.29% Shs Float29.00M Perf Month12.45%
Income-135.89M PEG- EPS next Q-1.18 Inst Own75.19% Short Float27.07% Perf Quarter46.97%
Sales17.45M P/S73.97 EPS this Y11.75% Inst Trans1.81% Short Ratio10.26 Perf Half Y145.33%
Book/sh5.76 P/B5.98 EPS next Y56.92% ROA-55.01% Short Interest7.85M Perf Year174.04%
Cash/sh6.07 P/C5.68 EPS next 5Y- ROE-69.71% 52W Range12.48 - 40.40 Perf YTD69.98%
Dividend Est.- P/FCF- EPS past 5Y-132.82% ROI-59.52% 52W High-14.80% Beta1.07
Dividend TTM- Quick Ratio6.85 Sales past 5Y-17.43% Gross Margin85.48% 52W Low175.80% ATR (14)1.94
Dividend Ex-Date- Current Ratio6.93 EPS Y/Y TTM-80.72% Oper. Margin-820.53% RSI (14)49.53 Volatility6.62% 5.51%
Employees244 Debt/Eq0.16 Sales Y/Y TTM-32.42% Profit Margin-778.89% Recom1.33 Target Price52.33
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q-157.80% Payout- Rel Volume0.00 Prev Close34.42
Sales Surprise138.99% EPS Surprise4.53% Sales Q/Q30.76% EarningsFeb 27 BMO Avg Volume764.87K Price34.42
SMA20-2.06% SMA502.38% SMA20055.62% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Neutral $19
Jul-18-23Initiated William Blair Outperform $44
May-18-23Initiated Guggenheim Buy
Aug-01-22Initiated Barclays Overweight $40
Dec-21-21Initiated H.C. Wainwright Buy $40
Nov-23-21Initiated Oppenheimer Outperform $55
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Apr-09-24 07:35AM
Apr-08-24 09:55AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
Mar-06-24 09:55AM
04:30PM Loading…
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
06:34AM
06:00AM
Feb-22-24 08:00AM
05:00PM Loading…
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
Dec-21-23 03:32PM
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
02:14PM Loading…
Aug-03-23 02:14PM
Aug-01-23 10:30PM
Jul-31-23 04:29PM
Jul-25-23 07:00AM
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Jun-05-23 08:30AM
May-09-23 04:05PM
May-08-23 08:30AM
May-05-23 08:22AM
May-03-23 04:30PM
Apr-24-23 08:30AM
Apr-18-23 06:04AM
Apr-06-23 03:52PM
Mar-17-23 06:28AM
Mar-13-23 04:05PM
Mar-09-23 10:00AM
Mar-02-23 04:30PM
Feb-24-23 11:44AM
Jan-24-23 04:33AM
Dec-16-22 07:00AM
Dec-15-22 12:45PM
08:30AM
Dec-08-22 06:55AM
Nov-11-22 06:03AM
Nov-09-22 08:45AM
07:00AM
Oct-25-22 08:30AM
Oct-17-22 09:26AM
Oct-11-22 08:30AM
Oct-06-22 08:30AM
Sep-29-22 08:30AM
Sep-27-22 12:00PM
Sep-17-22 10:23AM
Sep-07-22 07:00AM
Aug-11-22 05:25PM
04:05PM
Aug-05-22 08:30AM
Jul-25-22 08:00AM
Jun-29-22 06:51AM
May-27-22 09:00AM
May-14-22 08:19AM
May-11-22 06:30AM
May-10-22 06:55PM
04:05PM
May-09-22 01:49PM
May-06-22 09:00AM
May-05-22 08:30AM
May-03-22 03:00PM
06:58AM
May-02-22 07:01AM
07:00AM
Apr-29-22 09:23PM
Apr-26-22 08:30AM
Apr-21-22 03:05AM
Mar-14-22 04:05PM
Mar-09-22 05:00PM
Feb-03-22 09:00AM
Feb-02-22 04:30PM
07:00AM
Jan-04-22 09:00AM
Nov-23-21 04:30PM
Nov-10-21 04:30PM
Nov-09-21 04:05PM
Nov-05-21 12:04PM
Nov-04-21 11:28AM
09:45AM
Nov-02-21 05:00PM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Azamian Bobak R.President/CEO and Board ChairMar 18 '24Sale30.6010,415318,69926,456Mar 19 07:05 PM
Neervannan SeshadriChief Operating OfficerMar 18 '24Sale30.604,879149,29764,767Mar 19 07:03 PM
Mottiwala AzizChief Commercial OfficerMar 18 '24Sale30.604,766145,84054,075Mar 19 07:08 PM
Wahl BryanGeneral CounselMar 18 '24Sale30.604,436135,74240,951Mar 19 07:05 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 18 '24Sale30.604,314132,00834,181Mar 19 07:04 PM
Azamian Bobak R.President/CEO and Board ChairDec 27 '23Sale20.228,000161,760830,106Dec 29 05:08 PM
Azamian Bobak R.President/CEO and Board ChairDec 20 '23Sale20.2740,000810,623838,106Dec 22 05:30 PM
Trevejo Jose M.CHIEF MEDICAL OFFICERDec 20 '23Sale20.002,25245,0402,251Dec 22 05:32 PM
Goldberg Andrew D.DirectorDec 15 '23Buy18.961,00018,9603,000Dec 19 06:30 PM
Wahl BryanGeneral CounselNov 30 '23Sale16.318,356136,28631,966Dec 01 04:55 PM
Whitfield Dianne C.Chief Human Resources OfficerNov 30 '23Sale16.318,355136,27026,784Dec 01 04:58 PM
Whitfield Dianne C.Chief Human Resources OfficerNov 29 '23Option Exercise0.0023,920035,139Dec 01 04:58 PM
Wahl BryanGeneral CounselNov 29 '23Option Exercise0.0023,920040,322Dec 01 04:55 PM
Azamian Bobak R.President/CEO and Board ChairNov 15 '23Sale18.378,000146,933878,106Nov 17 04:50 PM
Azamian Bobak R.President/CEO and Board ChairOct 18 '23Sale13.248,000105,920886,106Oct 20 04:41 PM
Trevejo Jose M.CHIEF MEDICAL OFFICEROct 05 '23Sale18.001,60428,8724,503Oct 06 05:21 PM
Azamian Bobak R.President/CEO and Board ChairSep 20 '23Sale17.218,000137,680894,106Sep 22 05:30 PM
Azamian Bobak R.President/CEO and Board ChairAug 23 '23Sale17.238,000137,840902,106Aug 25 05:12 PM
Lin Elizabeth YeuDirectorAug 15 '23Buy16.809,506159,70115,866Aug 17 06:02 PM
Azamian Bobak R.President/CEO and Board ChairJul 19 '23Sale20.01103,9002,078,984910,106Jul 21 05:42 PM
Mottiwala AzizChief Commercial OfficerJul 19 '23Sale20.052,40048,12045,806Jul 21 05:46 PM
Azamian Bobak R.President/CEO and Board ChairJul 12 '23Sale17.359,000156,1501,014,006Jul 14 04:40 PM
Azamian Bobak R.President/CEO and Board ChairJun 21 '23Sale18.638,000149,0401,023,006Jun 23 04:29 PM
Azamian Bobak R.President/CEO and Board ChairJun 14 '23Sale18.589,000167,2201,031,006Jun 16 04:48 PM
Azamian Bobak R.President/CEO and Board ChairJun 08 '23Sale20.013,10062,0311,040,006Jun 12 05:40 PM
Mottiwala AzizChief Commercial OfficerJun 08 '23Sale20.001002,00048,086Jun 12 05:25 PM
Mottiwala AzizChief Commercial OfficerJun 07 '23Sale19.342,50048,35048,186Jun 08 07:16 PM
Mottiwala AzizChief Commercial OfficerJun 06 '23Sale18.612,14339,88150,686Jun 08 07:16 PM
Azamian Bobak R.President/CEO and Board ChairMay 17 '23Sale15.908,000127,2001,043,106May 19 07:08 PM
Azamian Bobak R.President/CEO and Board ChairMay 10 '23Sale16.809,000151,2001,051,106May 12 05:08 PM
Azamian Bobak R.President/CEO and Board ChairMay 01 '23Sale15.105,84188,1991,060,106May 02 07:06 PM
Azamian Bobak R.President/CEO and Board ChairApr 28 '23Sale15.134,27864,7261,065,947May 02 07:06 PM
Azamian Bobak R.President/CEO and Board ChairApr 21 '23Sale15.032,31134,7341,070,225Apr 25 05:22 PM
Greenstein Leonard M.Chief Financial OfficerApr 20 '23Sale14.025,00070,10026,785Apr 21 05:53 PM
Azamian Bobak R.President/CEO and Board ChairApr 19 '23Sale13.608,000108,8001,072,536Apr 21 05:49 PM